Efficacy of therapies in the treatment of Guillain-Barre Syndrome: a network meta-analysis

Objective: For comparing all of the therapies, such as immunoglobulin, plasma exchanging, etc. in the treatment of Guillain-Barre Syndrome(GBS) to better inform clinical practice, we used Network meta analysis to get the outcome of the Guillain-Barre Syndrome. The protocol had been submitted to PROSPERO:CRD: 42019119178. Methods: Web of Science, PubMed, Embase, and the Cochrane library were searched for related articles. We identified citations and of these included 28 trials comprising 2474 patients and control group human beings. Network meta-analysis (NMA) was performed with two kinds of outcomes. We carried on R software with gemtc package and JAGS software to calculate results for different therapies. The consistency of direct and indirect evidence was also assessed by R software. Results: Concerning for two outcomes, there were no improvement observed in methylprednisolone and prednisolone compared with placebo. PE and IVIg were illustrated to be effective over Placebo. There was no significant difference between different doses and times of PE and IVIg. On consistency examination between direct and indirect evidences, there were no obvious heterogeneity between all of therapies. Funnel plots indicates the possibility of publication bias in this study is small. Conclusion: PE or IVIg have a significant efficiency for GBS patients. The effect of some combination treatments should be further explored. Corticosteroids have no significant effects on GBS.

[1]  R. Hughes,et al.  CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY , 1978, The Lancet.

[2]  K. A. McCarter.  Plasma Exchange in Guillain-Barré Syndrome , 1982, Nursing times.

[3]  D. Chadwick,et al.  CONTROLLED TRIAL OF PLASMA EXCHANGE IN ACUTE INFLAMMATORY POLYRADICULONEUROPATHY , 1984, The Lancet.

[4]  R. Pirskanen,et al.  BENEFICIAL EFFECTS OF PLASMA EXCHANGE IN ACUTE INFLAMMATORY POLYRADICULONEUROPATHY , 1984, The Lancet.

[5]  Plasmapheresis and acute Guillain‐Barre syndrome , 1985, Neurology.

[6]  J. Raphael,et al.  Efficiency of plasma exchange in Guillain‐Barré syndrome: Role of replacement fluids , 1987, Annals of neurology.

[7]  J. Bussel,et al.  Combined plasma exchange and intravenous gammaglobulin in the treatment of patients with refractory immune thrombocytopenic purpura , 1988, Transfusion.

[8]  R. Hughes.  Plasma exchange for Guillain-Barré syndrome. , 1985, Journal of the Royal Society of Medicine.

[9]  P. Schmitz,et al.  A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. , 1992, The New England journal of medicine.

[10]  A. Ropper,et al.  Human immune globulin infusion in Guillain‐Barré syndrome , 1993, Neurology.

[11]  Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Guillain-Barré Syndrome Steroid Trial Group. , 1993, Lancet.

[12]  M. Osame,et al.  Immunoadsorption therapy for myasthenia gravis. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[13]  F. Mokhtarian,et al.  Treatment of myasthenia gravis by immunoadsorption of plasma , 1995, Neurology.

[14]  G. Pawlik,et al.  Sequential treatment of Guillain-Barré syndrome with extracorporeal elimination and intravenous immunoglobulin , 1996, Journal of the Neurological Sciences.

[15]  V. Bril,et al.  Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barre syndrome , 1996, Neurology.

[16]  N. K. Singh,et al.  Do corticosteroids influence the disease course or mortality in Guillain-Barre' syndrome? , 1996, The Journal of the Association of Physicians of India.

[17]  MD Jean-Claude Raphael,et al.  Appropriate number of plasma exchanges in Guillain‐Barré syndrome , 1997, Annals of neurology.

[18]  Plasma-ExchangeSandoglobulinGuillain-Barré Syndrome Trial Group.  Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome , 1997, The Lancet.

[19]  J H Rees,et al.  Epidemiological study of Guillain-Barré syndrome in south east England , 1998, Journal of neurology, neurosurgery, and psychiatry.

[20]  H. Willison,et al.  Randomized controlled trial of brain‐derived neurotrophic factor in Guillain–Barré syndrome: a pilot study , 2000, European journal of neurology.

[21]  X. Zhang,et al.  [Effect of Tripterygium polyglycoside on interleukin-6 in patients with Guillain-Barre syndrome]. , 2000, Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine.

[22]  R. Hughes,et al.  Intravenous immunoglobulin for Guillain-Barré syndrome. , 2001, The Cochrane database of systematic reviews.

[23]  S. Chevret,et al.  Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days , 2001, Journal of neurology, neurosurgery, and psychiatry.

[24]  H. Diener,et al.  A Preliminary, Randomized, Multicenter Study Comparing Intravenous Immunoglobulin, Plasma Exchange, and Immune Adsorption in Guillain-Barré Syndrome , 2001, European Neurology.

[25]  F. Weber,et al.  CSF filtration is an effective treatment of Guillain–Barré syndrome , 2001, Neurology.

[26]  F. Weber,et al.  CSF filtration is an effective treatment of Guillain–Barré syndrome: A randomized clinical trial , 2001 .

[27]  R. Hughes,et al.  A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome , 2003, Neurology.

[28]  J. Meulstee,et al.  Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial , 2004, The Lancet.

[29]  J. Raphaël,et al.  [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[30]  J. Schessl,et al.  Intravenously Administered Immunoglobulin in the Treatment of Childhood Guillain-Barré Syndrome: A Randomized Trial , 2005, Pediatrics.

[31]  R. Hughes,et al.  Intravenous immunoglobulin for Guillain-Barré syndrome. , 2006, The Cochrane database of systematic reviews.

[32]  Georgia Salanti,et al.  Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. , 2011, Journal of clinical epidemiology.

[33]  K. Knobloch,et al.  Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. , 2011, Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery.

[34]  M. El-Bayoumi,et al.  Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study , 2011, Critical care.

[35]  Nicky J Welton,et al.  Automating network meta‐analysis , 2012, Research synthesis methods.

[36]  Gerta Rücker,et al.  Network meta‐analysis, electrical networks and graph theory , 2012, Research synthesis methods.

[37]  M. Gill,et al.  Guillain-Barré syndrome. , 2012, The New England journal of medicine.

[38]  Harald Binder,et al.  A graphical tool for locating inconsistency in network meta-analyses , 2013, BMC Medical Research Methodology.

[39]  R. Hughes,et al.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. , 2013, The Cochrane database of systematic reviews.

[40]  Joseph Beyene,et al.  Network Meta-Analysis Using R: A Review of Currently Available Automated Packages , 2014, PloS one.

[41]  M. Zappia,et al.  Looks can be deceiving: three cases of neurological diseases mimicking Guillain–Barrè syndrome , 2016, Neurological Sciences.

[42]  S-L Li,et al.  Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian–Barre syndrome , 2015, Transfusion medicine.

[43]  R. Hughes,et al.  Corticosteroids for Guillain-Barré syndrome. , 2016, The Cochrane database of systematic reviews.

[44]  R. Hughes,et al.  Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. , 2016, The Cochrane database of systematic reviews.

[45]  A. McConnachie,et al.  Inhibition of complement in Guillain‐Barré syndrome: the ICA‐GBS study , 2017, Journal of the peripheral nervous system : JPNS.

[46]  G. Sobue,et al.  Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial , 2018, The Lancet Neurology.

[47]  S. Prinja,et al.  Cost‐minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin , 2018, Journal of clinical apheresis.

[48]  Audrey Béliveau,et al.  BUGSnet: an R package to facilitate the conduct and reporting of Bayesian network Meta-analyses , 2019, BMC Medical Research Methodology.